Synvista Therapeutics, Inc. (AMEX: SYI), a biopharmaceutical company, is focused on the development of drugs to treat and prevent cardiovascular disease and nephropathy in people with diabetes. The Company has identified multiple product candidates innovatively approach some of the largest pharmaceutical markets. The Company’s portfolio includes orally bioavailable, organoselenium mimics of glutathione peroxidase. For further information, visit the Company’s web site at www.alteon.com.
- 17 years ago
QualityStocks
Synvista Therapeutics, Inc. (AMEX: SYI)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – NextPlat Corp (NASDAQ: NXPL) Narrows Q2 Loss 66% as E-Commerce Growth Offsets Healthcare Headwinds
NextPlat (NASDAQ: NXPL, NXPLW), a global consumer products and services company in healthcare and technology,…
-
QualityStocksNewsBreaks – Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF) Stands Distinct Against Walker Lane Backdrop
Lahontan Gold (TSX.V: LG) (OTCQB: LGCXF) is positioned as investors view the Walker Lane corridor in…
-
QualityStocksNewsBreaks – Solowin Holdings (NASDAQ: SWIN) Targets $1 Billion AUM for Tokenized USD Money Market Product by Year-End 2025
Solowin (NASDAQ: SWIN), a financial services firm bridging traditional and digital assets, announced an initiative…